Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
05/2010
05/27/2010US20100130553 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxido-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in the treatment of cranial traumas
05/27/2010US20100130539 Imidazopyridine inhibitors of iap
05/27/2010US20100130538 Bicyclic compound and pharmaceutical use thereof
05/27/2010US20100130504 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
05/27/2010US20100130499 Bicycloheteroaryl compounds and their use as trpv1 ligands
05/27/2010US20100130492 Morpholinopurine derivatives
05/27/2010US20100130462 Lanolin compositions and methods for making and using same
05/27/2010US20100130438 Method for increasing oxytocin release in the epidermis
05/27/2010US20100129824 Distinguishing pca3 messenger rna species in benign and malignant prostate tissues
05/27/2010US20100129464 Manufacturing method and apparatus for producing substances that include negative hydrogen ion
05/27/2010US20100129452 Cellulose derivative and method for production thereof
05/27/2010US20100129368 Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof
05/27/2010US20100129342 Human Growth and Differentiation Factor GDF-5
05/27/2010US20100129336 Stabilized bacterial formulation
05/27/2010US20100129323 Novel Shuttle Vector
05/27/2010US20100129308 Polymers Functionalized with Ion-Specific Recognition Elements
05/27/2010CA2744012A1 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives
05/27/2010CA2742692A1 Use of escin for treatment of type iv hypersensitivity reaction
05/27/2010CA2741511A1 Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity
05/26/2010EP2189475A2 Fibroblast growth factor-like polypeptides
05/26/2010EP2189471A1 Foxm1 peptide and medicinal agent comprising the same
05/26/2010EP2189445A1 Five-membered heterocyclic compound
05/26/2010EP2189443A1 Tricyclic amide compound
05/26/2010EP2189440A1 Tricyclic amine compound
05/26/2010EP2189439A2 CaSR antagonist
05/26/2010EP2188254A1 Novel bradykinin b1-antagonists
05/26/2010EP2187901A2 Therapeutic use of neuropeptide ei and a acth 7-38 and compositions thereof
05/26/2010EP2187881A1 Powdered medicament for nasal delivery of ascorbic acid for reducing apomorphine induced toxicity to ciliated tissue
05/26/2010EP1947175B1 Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof
05/26/2010EP1572168B1 Anti-infarction molecules
05/26/2010EP1541155B1 Material for formation of carbon dioxide external preparation
05/26/2010EP1539137B1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
05/26/2010EP1497278B1 Heterocyclic amide derivatives as cytokine inhibitors
05/26/2010EP1461325B1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/26/2010EP1448602B1 Modified anti-tnf alpha antibody
05/26/2010EP1438321B1 Modified l-nucleic acid
05/26/2010EP1424998B1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
05/26/2010EP1370275B1 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
05/26/2010CN1935277B Preparation for the prophylaxis of restenosis
05/26/2010CN1930180B L-saccharide glucose lipid A analogue
05/26/2010CN1922183B Nitrogenous fused heteroaromatic ring derivative
05/26/2010CN1915991B Synthesis of indole thiazole compounds as ligands for the ah receptor
05/26/2010CN1886150B Fibroblast-mobilizing agent containing G-CSF and wound remedy
05/26/2010CN1870982B Composition containing reduced coenzyme q
05/26/2010CN1781545B Method for extracting herbal medicine
05/26/2010CN1733296B Stable liquid interferon formulations
05/26/2010CN1681811B Azolidinone-vinyl fused-benzene derivatives
05/26/2010CN1671407B Compositions and methods for treating diabetes
05/26/2010CN1662642B Pasteurisation process for microbial cells and microbial oil
05/26/2010CN1656073B Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
05/26/2010CN1655823B Topically applicable pharmaceutical preparation
05/26/2010CN1649883B Bicyclic 6-alkylidene-penems as lactamases inhibitors
05/26/2010CN1646138B Novel therapeutical use of agonist ligands specific to G2A receptor
05/26/2010CN1646124B Use of materials having zinc ionophoric behavior
05/26/2010CN1642580B Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
05/26/2010CN1596113B Use of delta receptor agonist compound in preparing medicine for treating depression
05/26/2010CN1578678B Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
05/26/2010CN1553814B Remedies for arteriosclerosis
05/26/2010CN1489580B 咪唑衍生物 Imidazole derivatives
05/26/2010CN1468308B Anti-TNF antibodies, compositions, methods and uses
05/26/2010CN1391469B Npyy5拮抗剂 Npyy5 antagonist
05/26/2010CN1359390B Factor VII a inhibitors
05/26/2010CN101712679A Acylamide class compound, medicine composition, preparation method and application thereof
05/26/2010CN101712657A heteroarylcarbamoylbenzene derivative
05/26/2010CN101712632A Substituted tetracycline compounds
05/26/2010CN101711868A Gene detection assay for improving the likelihood of an effective response to a ErbB antibody cancer therapy
05/26/2010CN101711767A Anti-sunstroke application of baicalin
05/26/2010CN101129960B Glutinous rehmannia soup against fatigue
05/26/2010CN101058564B Aryl alkyl carbamate derivatives production and use thereof in therapy
05/26/2010CN101019836B Nanometer cytochrome liposome medicine and its preparation
05/26/2010CN101003528B Diterpene compound and derivative in kaurene class of new dissymmetry, and its preparation method and uses
05/25/2010US7723500 Containing unmethylated CpG dinucleotides; redirection of a Th2 response to a Th1 response; atopic diseases, dermatitis; booster vaccines
05/25/2010US7723496 Tumor antigen for diagnosis and treatment of cell proliferative disorders
05/25/2010US7723490 Process for correction of a disulfide misfold in Fc molecules
05/25/2010US7723479 BSL3 polypeptides
05/25/2010US7723389 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
05/25/2010US7723373 3-(Aryl or heteroaryl)sulfonyl- or sulfinyl-1-indoleacetic acid derivatives, e.g., 3 -[(4-chlorophenyl)sulfonyl]-2,5-dimethyl-1H-indol-1-acetic acid; treating asthma, rhinitis and other diseases in which raised levels of PGD2 or its metabolites
05/25/2010US7723366 Cardiovascular disorders; antidiabetic agents; anticancer agents
05/25/2010US7723361 Kaposi's sarcoma; Crohn's disease; combination therapy with an epoxide hydrolase inhibitor
05/25/2010US7723357 Thalidomide and thalidomide derivatives for treating spinal disorders mediated by nucleus pulposus
05/25/2010US7723344 Dipeptidyl peptidase inhibitors
05/25/2010US7723339 signal transduction inhibitor is a PDGF receptor tyrosine kinase inhibitor or an active ingredient which decreases the activity of the epidermal growth factor; antiproliferative agent
05/25/2010US7723334 Highly selective norepinephrine reuptake inhibitors and methods of using the same
05/25/2010US7723022 Oligonucleotide containing activated lymphocytes; antibody therap y; skin disorders; antiallergens; respiratory system disorders
05/25/2010US7723017 Adding a metabolic supplement (such as pyruvate, inosine, adenine), and optionally dibasic sodium phosphate and/or monobasic sodium phosphate at least once to red blood cells; and storing under conditions of oxygen-free
05/25/2010CA2489337C Indole derivatives useful as histamine h3 antagonists
05/25/2010CA2489136C Novel 3-(4-oxo-40-chromen-2-yl)-(1h)-quinoline-4-one derivatives, method for preparing same and pharmaceutical compositions containing same
05/25/2010CA2439295C Carbamate compounds for use in preventing or treating neurodegenerative disorders
05/25/2010CA2433128C Novel quinuclidine derivatives and medicinal compositions containing the same
05/25/2010CA2403423C Tri-aryl-substituted-ethane pde4 inhibitors
05/25/2010CA2395461C Methods of modulating c-kit tyrosine kinase function with indolinone compounds
05/25/2010CA2376666C Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
05/25/2010CA2375727C Cytofectin dimers and methods of use thereof
05/25/2010CA2362279C Connective tissue softening
05/25/2010CA2330237C Broad specificity dna damage endonuclease
05/25/2010CA2321920C 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
05/25/2010CA2314156C Pyrrole substituted 2-indolinone protein kinase inhibitors
05/25/2010CA2223837C Aav transduction of myoblasts
05/25/2010CA2173130E Glutathione s-transferase-activated compounds
05/20/2010WO2010056145A1 Method for moderately increasing the proton conductivity of biological membranes with the aid of mitochondria-targeted delocalized cations
1 ... 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 ... 1564